Search results
Results from the WOW.Com Content Network
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India.It was founded by Kiran Mazumdar-Shaw in 1978. [4] The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, [5] including the United States and Europe. [4]
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania.The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. [8]In 1995, the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals, and Cadila Healthcare became the Patel family's holding company.
Pharmaceutical firm Mylan announced in a press statement this week that the company has agreed, with biotech firm Biocon, to establish a strategic partnership to develop and market three generic ...
Kiran Mazumdar-Shaw (born 23 March 1953) is an Indian billionaire entrepreneur. [3] She is the executive chairperson and founder of Biocon Limited and Biocon Biologics Limited, [4] a biotechnology company based in Bangalore, India [5] and the former chairperson of Indian Institute of Management, Bangalore. [6]
The average return after a stock split is announced in the year that follows is 25.4%. That's about a 13% greater return than the market over the same period. This chart lays it out nicely.
Nimotuzumab (h-R3, [2] BIOMAb EGFR, Biocon, India; [3] TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology, Havana, Cuba) is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was ...
The company initially started developing commercial processes for the manufacturing of APIs and intermediates. Divi's Research Centre changed its name to Divi's Laboratories Limited in 1994 to signal its intent to enter the API and intermediates manufacturing industry. [13]